Synthesis of a Conjugate of Gossypol with Doxorubicin

References

1. Keshmiri-Neghab H. Goliaei B. Therapeutic potential of gossypol: An overview. Pharm. Biol. 2014 52 1 124 128 10.3109/13880209.2013.832776 24073600
   [Google Scholar]
2. Lu Y. Li J. Dong C.E. Huang J. Zhou H.B. Wang W. Recent advances in gossypol derivatives and analogs: A chemistry and biology view. Future Med. Chem. 2017 9 11 1243 1275 10.4155/fmc‑2017‑0046 28722469
   [Google Scholar]
3. Liu Y. Wang L. Zhao L. Zhang Y. Structure, properties of gossypol and its derivatives—from physiological activities to drug discovery and drug design. Nat. Prod. Rep. 2022 39 6 1282 1304 10.1039/D1NP00080B 35587693
   [Google Scholar]
4. Li L. Li Z. Wang K. Liu Y. Li Y. Wang Q. Synthesis and antiviral, insecticidal, and fungicidal activities of gossypol derivatives containing alkylimine, oxime or hydrazine moiety. Bioorg. Med. Chem. 2016 24 3 474 483 10.1016/j.bmc.2015.08.015 26337022
   [Google Scholar]
5. Tien V.D. Van Vu V. Koeckritz A. Nhung T.T. Thao D.T. Vu T.K. Novel (-)-gossypol derived hydrazones: Synthesis and biological evaluation. AIP Conf. Proc. 2017 1878 020010 10.1063/1.5000178
   [Google Scholar]
6. Yang J. Chen G. Li L.L. Pan W. Zhang F. Yang J. Wu S. Tien P. Synthesis and anti-H5N1 activity of chiral gossypol derivatives and its analogs implicated by a viral entry blocking mechanism. Bioorg. Med. Chem. Lett. 2013 23 9 2619 2623 10.1016/j.bmcl.2013.02.101 23538114
   [Google Scholar]
7. Paunovic D. Rajkovic J. Novakovic R. Grujic-Milanovic J. Mekky R.H. Popa D. Calina D. Sharifi-Rad J. The potential roles of gossypol as anticancer agent: Advances and future directions. Chin. Med. 2023 18 1 163 10.1186/s13020‑023‑00869‑8 38098026
   [Google Scholar]
8. Pal D. Sahu P. Sethi G. Wallace C.E. Bishayee A. Gossypol and its natural derivatives: Multitargeted phytochemicals as potential drug candidates for oncologic diseases. Pharmaceutics 2022 14 12 2624 10.3390/pharmaceutics14122624 36559116
   [Google Scholar]
9. Xiong J. Li J. Yang Q. Wang J. Su T. Zhou S. Gossypol has anti-cancer effects by dual-targeting MDM2 and VEGF in human breast cancer. Breast Cancer Res. 2017 19 1 27 10.1186/s13058‑017‑0818‑5 28274247
   [Google Scholar]
10. Stepanov A.V. Yarovenko V.N. Nasyrova D.I. Dezhenkova L.G. Akchurin I.O. Krayushkin M.M. Ilyushenkova V.V. Shchekotikhin A.E. Tretyakov E.V. A spin-labeled derivative of gossypol. Molecules 2024 29 20 4966 10.3390/molecules29204966 39459334
    [Google Scholar]
11. Stepanov A.V. Yarovenko V.N. Krayushkin M.M. Reaction of gossypol with thiohydrazides of oxamic acids. Russ. Chem. Bull. 2024 73 2 437 441 10.1007/s11172‑024‑4150‑9
    [Google Scholar]
12. ubstituted derivatives of oxamic acid thiohydrazides, method for their preparation and their use. Patent RU2400471C1, 2009
13. Biologically active substances that suppress pathogenic bacteria. Patent RU2402531C2, 2008
14. Biologically active substances that suppress pathogenic bacteria, and a method for inhibiting type III secretion in pathogenic bacteria. Patent RU2447066C2, 2010
15. Linders A.N. Dias I.B. López Fernández T. Tocchetti C.G. Bomer N. Van der Meer P. A review of the pathophysiological mechanisms of doxorubicin-induced cardiotoxicity and aging. NPJ Aging 2024 10 1 9 10.1038/s41514‑024‑00135‑7 38263284
    [Google Scholar]
16. Renner O. Mayer M. Leischner C. Burkard M. Berger A. Lauer U.M. Venturelli S. Bischoff S.C. Systematic review of gossypol/AT-101 in cancer clinical trials. Pharmaceuticals 2022 15 2 144 10.3390/ph15020144 35215257
    [Google Scholar]
17. Peter S. Alven S. Maseko R.B. Aderibigbe B.A. Doxorubicin-based hybrid compounds as potential anticancer agents: A review. Molecules 2022 27 14 4478 10.3390/molecules27144478 35889350
    [Google Scholar]
18. Micallef I. Baron B. Doxorubicin: An overview of the anti-cancer and chemoresistance mechanisms. Ann. Clin. Toxicol 2020 3 2 1031
    [Google Scholar]
19. Kciuk M. Gielecińska A. Mujwar S. Kołat D. Kałuzińska-Kołat Ż. Celik I. Kontek R. Doxorubicin-an agent with multiple mechanisms of anticancer activity. Cells 2023 12 4 659 10.3390/cells12040659 36831326
    [Google Scholar]
20. Przybylski P. Huczynski A. Pyta K. Brzezinski B. Bartl F. Biological properties of Schiff bases and azo derivatives of phenols. Curr. Org. Chem. 2009 13 2 124 148 10.2174/138527209787193774
    [Google Scholar]
21. Nacaroğluballi J. Kirpik H. Köse M. A Gossypol-hydrazone compound and its sensing properties towards metal ions and nitro-phenolic compounds. J. Mol. Struct. 2021 1236 130310 10.1016/j.molstruc.2021.130310
    [Google Scholar]
22. Przybylski P. Małuszyńska M. Brzezinski B. Spectroscopic and semiempirical studies of new Schiff base of gossypol with allylamine in solution. J. Mol. Struct. 2005 750 1-3 152 157 10.1016/j.molstruc.2005.04.027
    [Google Scholar]
23. Tikhomirov A.S. Tsvetkov V.B. Volodina Y.L. Litvinova V.A. Andreeva D.V. Dezhenkova L.G. Kaluzhny D.N. Treshalin I.D. Shtil A.A. Shchekotikhin A.E. Heterocyclic ring expansion yields anthraquinone derivatives potent against multidrug resistant tumor cells. Bioorg. Chem. 2022 127 105925 10.1016/j.bioorg.2022.105925 35728293
    [Google Scholar]
24. Martins-Teixeira M.B. Carvalho I. Antitumour Anthracyclines: Progress and Perspectives. ChemMedChem 2020 15 11 933 948 10.1002/cmdc.202000131 32314528
    [Google Scholar]
25. Tikhomirov A.S. Litvinova V.A. Andreeva D.V. Tsvetkov V.B. Dezhenkova L.G. Volodina Y.L. Kaluzhny D.N. Treshalin I.D. Schols D. Ramonova A.A. Moisenovich M.M. Shtil A.A. Shchekotikhin A.E. Amides of pyrrole- and thiophene-fused anthraquinone derivatives: A role of the heterocyclic core in antitumor properties. Eur. J. Med. Chem. 2020 199 112294 10.1016/j.ejmech.2020.112294 32428792
    [Google Scholar]
26. Litvinova V.A. Tsvetkov V.B. Volodina Y.L. Dezhenkova L.G. Markova A.A. Nguyen M.T. Tikhomirov A.S. Shchekotikhin A.E. Naphthoindole-2-carboxamides as a lipophilic chemotype of hetarene-anthraquinones potent against P-gp resistant tumor cells. Eur. J. Med. Chem. 2025 281 117013 10.1016/j.ejmech.2024.117013 39500064
    [Google Scholar]